

Global mRNA Vaccines and Therapeutics Market Set to Reach USD 850.9 Million by 2033 | DataM Intelligence

The mRNA vaccine and therapeutics market focuses on innovative treatments using messenger RNA technology for various diseases.

“

The mRNA Vaccine and Therapeutics Market is rapidly growing, driven by innovations in infectious disease prevention and personalized medicine applications worldwide.

”

DataM Intelligence

AUSTIN, TX, UNITED STATES, May 23, 2025

/EINPresswire.com/ -- The Global [mRNA Vaccine and Therapeutics Market](#) is expected to see strong growth in the coming years. It's projected to rise from USD 410 million in 2024 to around USD 850.9 million by 2033, marking an average annual growth rate of 8.5%. This growth is being driven by several key trends ongoing innovations in personalized medicine, a rising number of chronic disease cases, and the continued success of mRNA-based COVID-19 vaccines in real-world use.

Market Overview:

mRNA vaccines and therapeutics represent a transformative approach in medicine, utilizing messenger RNA to instruct cells to produce proteins that elicit targeted immune responses. This technology has demonstrated efficacy in combating infectious diseases and holds promise for treating a range of chronic conditions, including cancer and autoimmune diseases. The market's growth is underpinned by increased research and development investments, technological advancements in delivery systems, and supportive regulatory frameworks.

Download Sample Report Here:

<https://www.datamintelligence.com/download-sample/mrna-vaccine-and-therapeutics-market>

Market Drivers and Opportunities:

Key factors driving market growth include:

Rising Incidence of Chronic Diseases:

The rising frequency of cancer, cardiovascular disease, and autoimmune illnesses is driving the need for novel therapeutic approaches.

Advancements in Personalized Medicine: mRNA technology enables the development of tailored treatments that address individual genetic profiles, enhancing treatment efficacy and patient outcomes.

Regulatory Support: Accelerated approvals and supportive policies from regulatory bodies are facilitating the rapid deployment of mRNA-based therapies.

Technological Innovations: Ongoing research into self-amplifying mRNA platforms and improved delivery mechanisms is enhancing the effectiveness and accessibility of mRNA therapeutics.

Market Segmentation:

By Product Type:

Prophylactic Vaccines

Therapeutic Vaccines

Therapeutic Drugs

By Application:

Cancer

Infectious Diseases


Rare Genetic Diseases

Others.

By End User:

Hospitals & Clinics

Research Organizations



Academic Institutes
Others.

By Region:

North America

South America

Europe

Asia Pacific

Middle East & Africa.

Geographical Market Share:

North America dominated the global market in 2024, with the United States dominating in terms of market size and technical breakthroughs. The region's supporting reimbursement policies, as well as its aging population, help it maintain market leadership.

The Asia-Pacific region is projected to experience the fastest growth during the forecast period, fueled by rising healthcare investments and an increasing prevalence of diseases in countries like China and Japan.

Key Market Players:

Prominent companies shaping the mRNA vaccines and therapeutics landscape include:

AstraZeneca

Pfizer Inc.

Moderna, Inc.

BioNTech SE.

Arcturus Therapeutics, Inc.

CureVac SE

Sanofi

etherna

These companies are at the forefront of developing and commercializing mRNA-based solutions, with ongoing clinical trials and strategic partnerships enhancing their market positions.

Recent Developments:

United States:

In May 2025, the U.S. Food and Drug Administration gave full approval to Novavax's COVID-19 vaccine, Nuvaxovid, specifically for people aged 65 and older, as well as those with certain health conditions. This decision is a big step forward for protein-based vaccines in the U.S., offering more options for those who need extra protection.

In May 2025, FDA advisers recommended updating COVID-19 vaccines to target newer strains of the JN.1 variant, specifically the LP.8.1 strain, which currently accounts for about 70% of U.S. cases. Vaccine producers, including Moderna, are preparing accordingly for a mid-August launch.

Japan:

In November 2023, Japan's Ministry of Health, Labor, and Welfare approved ARCT-154, the first self-amplifying mRNA COVID-19 vaccine globally. Developed by CSL and Arcturus Therapeutics, this vaccine represents a significant advancement in mRNA technology.

In March 2024, Strand Therapeutics discovered an improved class of mRNA molecules capable of detecting types of encountered cells and targeting diseased cells. This innovation holds promise for more precise and effective treatments.

Stay informed with the latest industry insights-start your subscription now:

<https://www.datamintelligence.com/reports-subscription>

Conclusion:

The mRNA vaccines and therapeutics market is undergoing a transformative phase, with significant advancements in technology and increasing global demand for personalized medicine. As regulatory support and technological innovations continue to evolve, the market is well-positioned for sustained growth, offering new hope for the treatment and prevention of various diseases.

Related Reports:

[RNAi Therapeutics Market](#)

[Maternal Health Market](#)

Sai Kiran

DataM Intelligence 4Market Research

+1 877-441-4866

Sai.k@datamintelligence.com

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/815433504>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.